HVR Cardio, an Espoo, Finland-based cardiovascular device company, raised $11.1M in Series B funding.
The round was led by Innovestor Life Science Fund and Tesi.
The company intends to use the funds to accelerate growth and expand operations.
Led by Tom Fleming, CEO, and Tim Girton, CTO, HVR Cardio is developing technology for transcatheter mitral valve repair with its CathHELIX™ Annuloplasty System, for use by Structural Heart Physicians to treat mitral regurgitation (MR). The CathHELIX device is an investigational technology and is not approved or cleared for use in patients in any geography
FinSMEs
12/01/2023